Label Update for Xtandi(r)

12 Sep 2014 10:27 AM | Lori Aubrey (Administrator)

The US Food and Drug Administration (FDA) has approved a new indication for XTANDI, an androgen receptor inhibitor. XTANDI is now indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

Read more about this update on the NNECOS Drug Related Resources, Packaging/Label Updates Page

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software